Rolph Timothy, the Chief Scientific Officer of Akero Therapeutics Inc . (NASDAQ:AKRO), recently executed a notable share sale ...

Graham G. Walmsley, a director at Akero Therapeutics, Inc. (NASDAQ:AKRO), recently acquired a significant amount of the company's common stock. According to a recent SEC filing, Walmsley purchased 200 ...

Akero Therapeutics has hit a home run, reporting statistically significant results in two key 96-week metabolic ...

NEW YORK CITY, NY / ACCESS Newswire / February 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

Akero Therapeutics, Inc. (NASDAQ:AKRO) released preliminary topline week 96 results from SYMMETRY Phase 2b study evaluating ...

We recently compiled a list of the 5 Stocks That Started The Year On A High. In this article, we are going to take a look at ...

Akero Therapeutics, Inc.’s AKRO share price has surged by 97.52%, which has investors questioning if this is right time to ...

Akero reported Monday strong results showing its drug efruxifermin reversed liver scarring in patients with cirrhosis caused ...

根据最新的SEC文件显示，Akero Therapeutics Inc. (NASDAQ: AKRO )的首席科学官Rolph Timothy近期进行了一笔重要的股票交易。值得注意的是，根据 InvestingPro ...

Akero Therapeutics reports a 39% improvement in cirrhosis patients using EFX. See why AKRO stock is soaring with the ...

旧金山讯—根据最新的SEC文件显示，Akero Therapeutics, Inc. (NASDAQ: AKRO )董事Graham G. Walmsley于1月30日以每股48美元的价格购入了200,000股公司普通股，总价值960万美元。该公司股票在过去一年上涨了191%，目前交易价格为54.21美元，已为这位董事的投资带来可观收益。 InvestingPro ...

We recently compiled a list of the 12 Best Booming Stocks to Invest in Now. In this article, we are going to take a look at ...